Search Results - drug+target

24 Results Sort By:
Safe and Highly Selective HDAC8 Inhibitors for Kidney Disease and Precision Therapies
HDAC8-targeting small molecules for kidney disease treatment with improved safety, selectivity, and therapeutic potential. Problem: Acute kidney injury (AKI) and focal segmental glomerulosclerosis (FSGS) affect millions of patients worldwide and can contribute to chronic kidney disease and end-stage renal failure, which only has a 5-year survival rate...
Published: 6/30/2026   |   Updated: 6/30/2026   |   Inventor(s): Donna Huryn, Neil Hukriede
Keywords(s): Drug Target, Nephrology and Urology, Small Molecule
Category(s): Technology Classifications > Chemical Processes and Synthesis, Technology Classifications > Research Tools & Reagents, Technology Classifications > Therapeutics
Small-Molecule Therapeutic for Stabilizing HIV-1 Envelope Proteins to Increase Immune Response
Small-molecule inhibitor that prolongs exposure of HIV-1 to broadly neutralizing antibodies to suppress viral entry and infection Problem: The human immunodeficiency virus (HIV-1) infects human cells through binding of its envelope proteins to surface-expressed CD4 and CCR5 receptors. Broadly neutralizing antibodies can recognize the native, functional...
Published: 6/25/2026   |   Updated: 6/25/2026   |   Inventor(s): Amos Smith, Althea Lang, Joseph Sodroski
Keywords(s): Drug Target, HIV/AIDS, Immunology, Infectious Disease
Category(s): Technology Classifications > Therapeutics, Technology Classifications > Chemical Processes and Synthesis
Increasing Efficiency of Anti-Tumor Immune Checkpoint Blockade Therapy by Manipulating Tumor-Associated Macrophages
A method to manipulate tumor-associated macrophages by targeting the mitochondrial electron transport chain, improving the efficacy of immune checkpoint blockade cancer therapies. Problem: Many cancer therapeutics work by activating the immune system to attack a tumor. These drugs, known as immune checkpoint blockade (ICB) therapies, commonly fail because...
Published: 5/13/2026   |   Updated: 5/13/2026   |   Inventor(s): Jorge Henao-Mejia, Megan Clark
Keywords(s): Drug Target, Immunology, Oncology
Category(s): Technology Classifications > Therapeutics
Pharmacological Treatment for Sleep Disorders Improving Sleep Quality & Architecture
Targeting Heat Shock Factor 1 (HSF1) via gene therapy or using pharmacological compounds targeting HSF1 (e.g. geranylgeranylacetone or macrocyclic peptides) can increase sleep stability, promote deeper sleep, reduce sleep fragmentation, and improve recovery from sleep loss. Problem: Millions of people worldwide suffer from disrupted sleep, whether due...
Published: 4/16/2026   |   Updated: 4/14/2026   |   Inventor(s): Akhilesh Basi Reddy, Shintaro Yamazaki
Keywords(s): Aging, Drug Target, Gene Therapy, Neurodegenerative Diseases, Protein/Peptide (Non-Antibody), Small Molecule, Women's Health
Category(s): Technology Classifications > Therapeutics
Mechanically Tunable Engineered Heart Tissue Platform
Next-generation engineered heart tissue platform that enables precise tuning of mechanical properties of microenvironment to study the structure, development, and function of cultured cells or human-derived cardiac tissues. Problem: Engineering heart tissue (EHT) platforms have the potential to study heart physiology, disease pathology, and therapeutic...
Published: 1/30/2026   |   Updated: 1/30/2026   |   Inventor(s): Kenneth Margulies, Benjamin Lee, Nesrine Bouhrira
Keywords(s): Bioengineering, Cardiovascular, Drug Target, Platform Technology
Category(s): Technology Classifications > Hardware & Components, Technology Classifications > Research Tools & Reagents, Technology Classifications > Testing & Measurement
Anticancer IgG Against Multiple Epitopes on Live Tumors Upon Disruption of ‘Self’ Signaling by CD47
A method to combine two or three monoclonal antibodies (mABs) into one treatment to successfully bind to multiple cancer cell surface epitopes and promote targeted degradation by phagocytosis. Problem: Phagocytosis of ‘self’ cells is generally inhibited by a key macrophage checkpoint interaction between SIRPα on the macrophage and...
Published: 12/15/2025   |   Updated: 12/15/2025   |   Inventor(s): Dennis Discher, Jason Andrechak, Lawrence Dooling
Keywords(s): Antibody, Bioengineering, Cell Therapy, Drug Target, Immunology, Immunoncology, Immunotherapy, Oncology, Platform Technology
Category(s): Technology Classifications > Therapeutics
A Potent HIV Treatment with Low Toxicity
A small-molecule class that binds to HIV particles to improve immune response and block viral entry into cells. Problem: 37 million people worldwide currently live with HIV and an estimated 2-3 million new infections occur annually. While antiretroviral therapies do exist for those with the disease, therapy interruption leads to the re-emergence of...
Published: 11/11/2025   |   Updated: 10/30/2025   |   Inventor(s): Amos Smith, Xuchen Zhao, Tyler Higgins, Andres Finzi, Shilei Ding, Daniel Lee, Marzena Pazgier, Dung Nguyen, William Tolbert
Keywords(s): Drug Target, HIV/AIDS, Small Molecule, Soft Materials
Category(s): Technology Classifications > Chemical Processes and Synthesis, Technology Classifications > Therapeutics
Adhesive Microparticle Formulation For Localized And Sustained Drug Delivery
A hairy, water-in-oil-in-water microemulsion for prolonged delivery of one or more active ingredients while adhering to target tissues. Problem: Microparticles are promising drug delivery platforms due to their biocompatibility and stability. However, existing particle-based drug delivery systems are unable to fulfill the needs for prolonged delivery...
Published: 10/3/2025   |   Updated: 11/13/2024   |   Inventor(s): Daeyeon Lee, Minjun Oh, Jaehyun Kim, Li-Wei Chang, Robert Mauck, George Dodge, Hyun (Michel) Koo
Keywords(s): Bioengineering, Dentistry, Drug Delivery, Drug Target
Category(s): Technology Classifications > Materials
Silencing of PRLΔE1 expression: a gene-agnostic treatment for retinal degenerations
Viral vector-mediated gene silencing of a novel short retinal isoform of Prolactin promotes photoreceptor survival. Problem: Age-related macular degeneration (AMD) and inherited retinal degeneration (IRDs) have extreme mutational heterogeneity, and many IRDs are orphan diseases. Developing individual gene therapies for each causative gene is impractical...
Published: 9/8/2025   |   Updated: 3/12/2024   |   Inventor(s): William Beltran, Raghavi Sudharsan
Keywords(s): Drug Target, Gene Therapy, Genetic Disorders, Neurodegenerative Diseases, Ophthalmology, Orphan Disease
Category(s): Technology Classifications > Therapeutics
Topical LSD1 Inhibition for Treating Skin Diseases
Topical LSD1 inhibition can treat skin diseases that include cutaneous squamous cell carcinoma (cSCC), actinic keratoses, and viral warts. Problem: Current treatment options (i.e. cryotherapy, laser therapy, surgery, chemotherapy) for skin diseases such as cSCC, actinic keratoses, and viral warts are often non-targeted and destructive, and can cause...
Published: 5/11/2026   |   Updated: 11/8/2023   |   Inventor(s): Brian Capell, Napasorn (Nina) Kuprasertkul
Keywords(s): Dermatology, Drug Delivery, Drug Target, Immunoncology, Oncology
Category(s): Technology Classifications > Therapeutics
1 2 3